Akebia Secures New Vafseo Patent, Extends Key IP to 2032
AKBA is trading near its 52-week low of $0.875 (4.8% above the low).
Summary
Akebia Therapeutics announced a new patent for its key drug Vafseo (vadadustat) has been granted, and a composition of matter patent is eligible for a five-year extension, pushing its expiration to mid-2032. This significantly strengthens the intellectual property for Vafseo, which is the company's primary growth product and the only oral HIF-PH inhibitor in the U.S. The extended exclusivity is crucial for Akebia, especially after recent Q1 results showed a net loss and generic competition impacted their Auryxia drug. This development provides a longer revenue runway and reduces the risk of early generic competition for their most important asset.
At the time of this announcement, AKBA was trading at $0.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $246.8M. The 52-week trading range was $0.88 to $4.08. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.